Antiarrhythmic Drugs in Atrial Fibrillation: Do They Have a Future?

Abstract Atrial fibrillation (AF) is a common arrhythmia associated with significant morbidity and mortality. There has been much debate about the relative merits of rate vs rhythm control strategies, and studies to date have failed to show advantage with a rhythm-control strategy using antiarrhythm...

Full description

Saved in:
Bibliographic Details
Published in:Canadian journal of cardiology 2013-10, Vol.29 (10), p.1158-1164
Main Authors: Angaran, Paul, MD, Dorian, Paul, MD
Format: Article
Language:English
Subjects:
Anti-Arrhythmia Agents - therapeutic use
Atrial Fibrillation - drug therapy
Atrial Fibrillation - physiopathology
Cardiovascular
Forecasting
Heart Rate - drug effects
Humans
Quality of Life
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Atrial fibrillation (AF) is a common arrhythmia associated with significant morbidity and mortality. There has been much debate about the relative merits of rate vs rhythm control strategies, and studies to date have failed to show advantage with a rhythm-control strategy using antiarrhythmic drugs (AADs). This is likely because of the inadequacies of our current AADs and the limitations of study designs. However, there is evidence that AADs improve symptoms and quality of life (QOL). Until trials are performed with more appropriate patient selection, and end points and better AADs and strategies for their use, rhythm control should not be abandoned and may continue to be beneficial in selected patients.
ISSN:0828-282X
1916-7075
DOI:10.1016/j.cjca.2013.04.033